long term effects of glp-1 drugs A monthly dose could cut the number shots patients take each year from 52 to 12. Side from the drug — mainly gastrointestinal symptoms — were similar to or GLP-1 Receptor Agonists | New
Description
Glucagon-like peptide1 receptor agonists (GLP-1RAs) have emerged as a transformative class of therapies initially developed for glycemic control in type2 diabetes mellitus
These products are not intended to diagnose, treat, cure, or prevent any disease
At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide
There are no large trials proving safety, but early data suggests milk transfer is low
Here, we report three cryo-electron microscopy structures of GLP-1R bound to (i) compound 2 (an ago-allosteric modulator)
